Skip to main content
PVCT logo

Provectus Biopharmaceuticals, Inc. (PVCT) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0425 -$0.0001 (-0.23%)
MCap: $17.9M| Vol: 15.0K|

Market cap $17.9M is the value of all shares combined. Beta 0.84: the stock has moved about 16% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Provectus Biopharmaceuticals, Inc. (PVCT) trades at $0.0425. Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing immunotherapy treatments for various cancers and inflammatory skin conditions. Market cap: $17.9M, Sector: Healthcare.

Price as of · Last analyzed: Jun 14, 2026
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing immunotherapy treatments for various cancers and inflammatory skin conditions. The company leverages its proprietary halogenated xanthene platform to advance its innovative therapies, including PV-10 and PH-10.

Analyst Coverage for PVCT: PVCT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Provectus Biopharmaceuticals, Inc. (PVCT) Healthcare & Pipeline Overview

CEOEdward V. Pershing
Employees6
HeadquartersKnoxville, US
IPO Year1997

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in immunotherapy treatments, with a focus on its proprietary halogenated xanthene platform and investigational drugs targeting solid tumors and inflammatory skin conditions, positioning it uniquely within the competitive landscape of cancer therapeutics.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for PVCT?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Provectus Biopharmaceuticals, Inc. presents a unique investment thesis driven by its innovative drug pipeline, particularly PV-10 and PH-10, which target significant unmet medical needs in oncology and dermatology. The company is currently engaged in multiple clinical trials, which could serve as key value drivers, especially if positive results are achieved. With a market cap of $17.9M and a gross margin of 96.8%, the company is positioned for potential growth as it advances its therapies through clinical stages. However, the high profit margin of -9775.3% reflects the challenges of being a clinical-stage company, emphasizing the importance of successful trial outcomes and regulatory approvals. Investors should monitor the progress of clinical trials and the potential for uplisting to a more recognized exchange, which could enhance liquidity and visibility.

Based on FMP financials and quantitative analysis

PVCT Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $17.9M indicates a small-cap status with potential for growth.

  • Gross Margin of 96.8% highlights the high value of its proprietary therapies.
  • Profit Margin of -9775.3% reflects the challenges faced by clinical-stage companies.
  • Beta of 0.84 suggests lower volatility compared to the broader market.
  • No dividend yield, consistent with typical biotechnology firms focused on reinvestment.

Who Are PVCT's Competitors?

PVCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
IMV IMV Inc. $0.82 0.00% $9.63M —
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar
FENC Fennec Pharmaceuticals Inc. $13.33 -1.84% $471M 91 5-pillar
INDP Indaptus Therapeutics, Inc. $3.13 -4.86% $481M 60 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PVCT's Key Strengths?

Innovative drug pipeline with a focus on immunotherapy.

  • High gross margin indicating potential profitability upon commercialization.
  • Experienced management team with a clear strategic vision.

What Are PVCT's Weaknesses?

High profit margin indicating significant operational losses.

  • Limited employee base may restrict development capabilities.
  • Dependency on clinical trial outcomes for future success.

What Could Drive PVCT Stock Higher?

PVCT catalyst: Clinical trials for PV-10 and PH-10 are currently underway, with results expected to impact the company's future market position.

  • Potential partnerships with larger pharmaceutical companies could be announced, enhancing development capabilities.
  • Plans for uplisting to a major exchange may be explored, increasing visibility and liquidity.
  • Advancements in oral formulations of pharmaceutical-grade rose bengal sodium are being pursued, targeting a wide range of conditions.

What Are the Key Risks for PVCT?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

  • High dependence on the success of clinical trials for future revenue generation.
  • Regulatory challenges may delay product approvals and market entry.
  • Competition from other biotechnology firms developing similar therapies.
  • Market volatility affecting investor sentiment towards clinical-stage biotechnology companies.

What Are the Growth Opportunities for PVCT?

  • Expansion of Clinical Trials: Provectus is currently advancing multiple clinical trials for PV-10 and PH-10, targeting various solid tumors and inflammatory skin conditions.
  • Development of Oral Formulations: The advancement of oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) represents a significant growth opportunity. This product aims to address a wide range of conditions, including adult solid tumors and acute respiratory syndromes, tapping into the growing market for oral cancer therapies, which is projected to grow at a CAGR of 8% over the next five years.
  • Potential for Pediatric Market Penetration: With its focus on pediatric solid tumors, Provectus has the opportunity to enter a niche yet critical market. The pediatric oncology market is estimated to grow at a CAGR of 5% through 2028, driven by increased awareness and advancements in treatment options.
  • Strategic Partnerships and Collaborations: Establishing partnerships with larger pharmaceutical companies could enhance Provectus's development capabilities and market reach. Collaborations can provide access to additional resources, funding, and expertise, which can accelerate the development of its pipeline products.
  • Uplisting to a Major Exchange: The potential for Provectus to uplist from the OTC market to a major exchange such as NASDAQ could significantly increase its visibility and liquidity. This transition could attract institutional investors and improve the company's overall market perception.

What Threats Does PVCT Face?

  • Intense competition in the biotechnology sector.
  • Regulatory hurdles associated with drug approval processes.
  • Market volatility affecting investor sentiment towards biotechnology stocks.

What Are PVCT's Competitive Advantages?

  • Proprietary halogenated xanthene platform provides a unique competitive advantage.
  • Focus on unmet medical needs in oncology and dermatology enhances market positioning.
  • Ongoing clinical trials demonstrate commitment to research and development.

What Does PVCT Do?

Provectus Biopharmaceuticals, Inc., founded in 2002 and initially named Provectus Pharmaceuticals, Inc., is a clinical-stage biotechnology firm headquartered in Knoxville, Tennessee. The company is dedicated to pioneering immunotherapy treatments utilizing its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy currently being investigated for a variety of adult solid tumor malignancies, including melanoma and several gastrointestinal cancers, such as hepatocellular carcinoma and metastatic colorectal cancer. Additionally, PV-10 is being explored for pediatric solid tumors like neuroblastoma and Ewing sarcoma. Provectus is further advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS), which aims to address a wide range of conditions, including adult solid tumors, pediatric blood cancers, acute respiratory syndromes, and infections caused by multi-drug resistant bacteria. The company is also developing PH-10, an investigational immuno-dermatology agent targeting inflammatory skin conditions such as psoriasis and atopic dermatitis. Since its rebranding in December 2013, Provectus has focused on establishing itself as a leader in the biotechnology sector, particularly in immunotherapy, demonstrating a commitment to research and development through ongoing clinical trials.

What Products and Services Does PVCT Offer?

  • Develops immunotherapy treatments for various cancers and inflammatory skin conditions.
  • Focuses on proprietary halogenated xanthene platform for drug development.
  • Key product PV-10 is an experimental autolytic cancer immunotherapy.
  • Advances oral formulations of pharmaceutical-grade rose bengal sodium.
  • Targets a broad spectrum of conditions, including solid tumors and infections.
  • Conducts clinical trials to validate the efficacy of its therapies.

How Does PVCT Make Money?

  • Primarily generates revenue through the development and potential commercialization of innovative therapies.
  • Focuses on clinical trial outcomes to advance products toward regulatory approval.
  • Explores partnerships and collaborations to enhance development and distribution capabilities.

What Industry Does PVCT Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the fields of oncology and immunotherapy. The global cancer therapeutics market is projected to grow substantially, driven by increasing cancer prevalence and advancements in treatment modalities. Provectus Biopharmaceuticals, Inc. operates in a competitive landscape alongside other biotechnology firms, focusing on immunotherapy, which is gaining traction due to its potential for personalized medicine. The company's unique approach with its halogenated xanthene platform positions it to capitalize on the growing demand for effective cancer treatments.

Who Are PVCT's Key Customers?

  • Healthcare providers and institutions involved in cancer treatment.
  • Patients seeking innovative therapies for solid tumors and inflammatory skin conditions.
  • Pharmaceutical partners interested in collaboration for drug development.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage

Insider Activity

14 transactions · 0 purchases, 0 sales, 14 other transactions · 4 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

PVCT Valuation & Market Position

With a $17.9M market cap, Provectus Biopharmaceuticals, Inc. sits in the micro-cap segment of the market.

ROE 75%

Key Financial Metrics

Return on equity for Provectus Biopharmaceuticals, Inc. stands at 74.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -12.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.18 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -25.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9

Financial Health

Provectus Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

Provectus Biopharmaceuticals, Inc. operates in the Healthcare sector. It is headquartered in Knoxville, United States.

PVCT Financials

Bull Case vs Bear Case

Bull Case

  • Innovative drug pipeline with a focus on immunotherapy.
  • High gross margin indicating potential profitability upon commercialization.
  • Experienced management team with a clear strategic vision.
  • Ongoing: Clinical trials for PV-10 and PH-10 are currently underway, with results expected to impact the company's future market position.

Bear Case

  • High profit margin indicating significant operational losses.
  • Limited employee base may restrict development capabilities.
  • Dependency on clinical trial outcomes for future success.
  • Potential: High dependence on the success of clinical trials for future revenue generation.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

PVCT Latest News

PVCT Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PVCT.

Price Targets

Wall Street price target analysis for PVCT.

PVCT MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PVCT; grades run from A+ (80-100) to F (below 30).

Leadership: Edward V. Pershing

CEO

Edward V. Pershing has a significant background in the biotechnology and pharmaceutical industries, having held various leadership roles throughout his career. He has extensive experience in corporate management, strategic planning, and product development, which has been instrumental in guiding Provectus Biopharmaceuticals towards its current focus on innovative therapies. His educational background and professional credentials further enhance his capability in leading the company.

Track Record: Under Edward V. Pershing's leadership, Provectus has advanced its clinical pipeline, focusing on key investigational drugs such as PV-10 and PH-10. His strategic decisions have helped position the company within the competitive biotechnology landscape, emphasizing research and development.

PVCT OTC Market Information

The OTC Other tier represents stocks that do not meet the criteria for more regulated exchanges like NYSE or NASDAQ. These stocks may have lower liquidity, less stringent reporting requirements, and higher volatility, making them riskier investments. Investors should be cautious and conduct thorough due diligence when considering such stocks.

  • OTC Tier: OTC Other
Liquidity: Trading volume for OTC stocks can be lower than that of stocks on major exchanges, potentially leading to wider bid-ask spreads and difficulty executing trades at desired prices. Investors should be aware of these liquidity challenges when considering positions in PVCT.
OTC Risk Factors:
  • Limited liquidity may result in increased price volatility.
  • Regulatory scrutiny can impact the company's operations and stock performance.
  • Dependence on clinical trial outcomes introduces significant risk.
Due Diligence Checklist:
  • Verify the company's clinical trial progress and results.
  • Assess the financial health and cash runway of Provectus.
  • Review any potential partnerships or collaborations in development.
  • Monitor regulatory developments and market conditions affecting the biotechnology sector.
  • Evaluate the management team's experience and track record.
Legitimacy Signals:
  • Established history since 2002, indicating stability.
  • Focused research and development efforts on innovative therapies.
  • Engagement in clinical trials demonstrates commitment to advancing its pipeline.

Provectus Biopharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Is PVCT a good stock to buy?

Stock Expert AI does not rate PVCT buy, sell or hold. Provectus Biopharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PVCT stock price today?

The last price recorded on this page for Provectus Biopharmaceuticals, Inc. (PVCT) is $0.0425, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is Provectus Biopharmaceuticals, Inc.'s drug pipeline status?

Provectus Biopharmaceuticals, Inc. is actively engaged in clinical trials for its key investigational drugs, PV-10 and PH-10. These drugs are being evaluated for their efficacy in treating various solid tumors and inflammatory skin conditions.

What are the key factors to evaluate for PVCT?

Evaluate PVCT on fundamentals, analyst consensus, and risk factors. With a market cap of $17.9M and a gross margin of 96.8%, the company is positioned for potential growth as it advances its therapies through clinical stages. Not financial advice.

How frequently does PVCT data refresh on this page?

PVCT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PVCT's recent stock price performance?

Provectus Biopharmaceuticals, Inc. (PVCT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline with a focus on immunotherapy. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PVCT overvalued or undervalued right now?

Provectus Biopharmaceuticals, Inc. (PVCT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PVCT before investing?

Before investing in Provectus Biopharmaceuticals, Inc. (PVCT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Data is based on the latest available information and may be subject to change.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives